

Steven M Horwitz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5458258/publications.pdf>

Version: 2024-02-01

142
papers

6,666
citations

101543

36
h-index

66911

78
g-index

142
all docs

142
docs citations

142
times ranked

6451
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring. <i>Clinical Cancer Research</i> , 2022, 28, 45-56.	7.0	13
2	Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma. <i>Blood Cancer Journal</i> , 2022, 12, 29.	6.2	1
3	T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 285-308.	4.9	58
4	CD117 improves accurate detection of Sezary cells by flow cytometry in peripheral blood in mycosis fungoides/Sezary syndrome. <i>Cytometry Part B - Clinical Cytometry</i> , 2022, 102, 189-198.	1.5	5
5	First report of bilateral breast-implant associated anaplastic large cell lymphoma caused by identical T-cell clone. <i>Leukemia and Lymphoma</i> , 2022, 63, 2747-2750.	1.3	2
6	Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era. <i>Blood</i> , 2021, 137, 39-48.	1.4	38
7	Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 97-105.	0.4	18
8	Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies. <i>Clinical Cancer Research</i> , 2021, 27, 2190-2199.	7.0	110
9	Next generation sequencing of breast implant-associated anaplastic large cell lymphomas reveals a novel <i>STAT3&JAK2</i> fusion among other activating genetic alterations within the <i>JAK&STAT</i> pathway. <i>Breast Journal</i> , 2021, 27, 314-321.	1.0	29
10	Outcomes and Prognostic Factors in Angioimmunoblastic T cell Lymphoma: Final Report from the International TCell Project. <i>Blood</i> , 2021, 138, 213-220.	1.4	53
11	Outcomes of adult T-Cell leukemia/lymphoma with allogeneic stem cell transplantation: single-institution experience. <i>Leukemia and Lymphoma</i> , 2021, 62, 2177-2183.	1.3	2
12	Oncologic immunomodulatory agents in patients with cancer and COVID-19. <i>Scientific Reports</i> , 2021, 11, 4814.	3.3	11
13	Molecularly targeted therapies for relapsed and refractory peripheral T-cell lymphomas. <i>Seminars in Hematology</i> , 2021, 58, 78-84.	3.4	2
14	Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis. <i>European Journal of Cancer</i> , 2021, 148, 411-421.	2.8	27
15	Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse. <i>Blood Cancer Journal</i> , 2021, 11, 113.	6.2	35
16	Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study. <i>Lancet Haematology</i> , 2021, 8, e433-e445.	4.6	53
17	Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2257-2265.	1.6	32
18	Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts. <i>American Journal of Hematology</i> , 2021, 96, 1211-1222.	4.1	16

#	ARTICLE	IF	CITATIONS
19	Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data. <i>Blood Advances</i> , 2021, 5, 5098-5106.	5.2	46
20	Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3109-3117.	1.6	97
21	Impact of Choice of Platinum-Based Salvage Therapy on CNS Relapse in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 2529-2529.	1.4	0
22	TP53 Mutations Identify High-Risk Peripheral T-Cell Lymphoma Patients Treated with CHOP-Based Chemotherapy. <i>Blood</i> , 2021, 138, 1367-1367.	1.4	2
23	Clinical Outcomes and CNS Relapse Risk in Patients with Primary Cutaneous DLBCL, Leg Type Treated in the Rituximab Era: Long-Term Follow-up of a Single-Center Experience. <i>Blood</i> , 2021, 138, 2513-2513.	1.4	0
24	How we treat mycosis fungoides and S�azary syndrome. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19, 573-581.	0.3	0
25	Outcomes and prognostic factors in African American and black patients with mycosis fungoides/S�azary syndrome: Retrospective analysis of 157 patients from a referral cancer center. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 430-439.	1.2	34
26	Fear of cancer recurrence in lymphoma survivors: A descriptive study. <i>Journal of Psychosocial Oncology</i> , 2020, 38, 251-271.	1.2	11
27	Incidence of benign and malignant peri-implant fluid collections and masses on magnetic resonance imaging in women with silicone implants. <i>Cancer Medicine</i> , 2020, 9, 3261-3267.	2.8	13
28	C�C chemokine receptor 4 expression in CD8+ cutaneous T�cell lymphomas and lymphoproliferative disorders, and its implications for diagnosis and treatment. <i>Histopathology</i> , 2020, 76, 222-232.	2.9	6
29	Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas. <i>American Journal of Hematology</i> , 2020, 95, 151-155.	4.1	43
30	Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies. <i>Blood Advances</i> , 2020, 4, 4669-4678.	5.2	64
31	Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. <i>Blood Cancer Journal</i> , 2020, 10, 74.	6.2	81
32	Targeted genomic analysis of cutaneous T cell lymphomas identifies a subset with aggressive clinicopathological features. <i>Blood Cancer Journal</i> , 2020, 10, 116.	6.2	6
33	Modified SMILE (mSMILE) and intensity-modulated radiotherapy (IMRT) for extranodal NK-T lymphoma nasal type in a single-center population. <i>Leukemia and Lymphoma</i> , 2020, 61, 3331-3341.	1.3	17
34	A Novel JAK1 Mutant Breast Implant-Associated Anaplastic Large Cell Lymphoma Patient-Derived Xenograft Fostering Pre-Clinical Discoveries. <i>Cancers</i> , 2020, 12, 1603.	3.7	11
35	Bright PD-1 expression by flow cytometry is a powerful tool for diagnosis and monitoring of angioimmunoblastic T-cell lymphoma. <i>Blood Cancer Journal</i> , 2020, 10, 32.	6.2	9
36	Cancer worry and empathy moderate the effect of a survivorship-focused intervention on quality of life. <i>Psycho-Oncology</i> , 2020, 29, 1012-1018.	2.3	13

#	ARTICLE	IF	CITATIONS
37	Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project. <i>Lancet Haematology</i> , 2020, 7, e284-e294.	4.6	78
38	The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma. <i>Blood</i> , 2020, 136, 3-5.	1.4	11
39	Multi-Center Phase II Study of Oral Azacitidine (CC-486) Plus CHOP As Initial Treatment for Peripheral T-Cell Lymphoma (PTCL). <i>Blood</i> , 2020, 136, 33-34.	1.4	19
40	Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, Is Well-Tolerated and Active in Patients with T-Cell Lymphoma. <i>Blood</i> , 2020, 136, 19-20.	1.4	7
41	Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 17-18.	1.4	5
42	End of Treatment Peripheral Blood T-Cell Receptor Gene Rearrangement Evaluation for Minimal Residual Disease Evaluation in Peripheral T-Cell Lymphomas. <i>Blood</i> , 2020, 136, 30-31.	1.4	2
43	Interim Analysis from a Prospective Multicenter Study of Next-Generation Sequencing Minimal Residual Disease Assessment and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 46-47.	1.4	3
44	Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Dose Optimization Efficacy Update and Expansion Phase Initial Results. <i>Blood</i> , 2020, 136, 38-39.	1.4	14
45	CD5-Positive Marginal Zone Lymphoma: Clinical Characteristics of the MSKCC Cohort, and Comparison with the CD5-Negative Population. <i>Blood</i> , 2020, 136, 50-51.	1.4	2
46	T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 4640-4647.	5.2	50
47	Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies. <i>Blood</i> , 2020, 136, 41-43.	1.4	5
48	Favorable Outcomes Among Patients with T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Treated with Higher-Intensity Therapy in the Rituximab Era. <i>Blood</i> , 2020, 136, 36-38.	1.4	1
49	Trial-in-Progress: Frontline Brentuximab Vedotin and CHP (A+CHP) in Patients with Peripheral T-Cell Lymphoma with Less Than 10% CD30 Expression. <i>Blood</i> , 2020, 136, 30-30.	1.4	2
50	Successful Treatment of Mature T-Cell Lymphoma with Allogeneic Stem Cell Transplantation: The Largest Multicenter Retrospective Analysis. <i>Blood</i> , 2020, 136, 35-36.	1.4	7
51	A Critical Role for Patient Education in Improving Patient-Provider Communication and Treatment Decisions across Rare Hematologic Malignancies. <i>Blood</i> , 2020, 136, 41-41.	1.4	0
52	Clinical Characteristics and Follow-up Post-Surgery of Women with Bia-ALCL Operated at a Single Institution. <i>Blood</i> , 2020, 136, 32-33.	1.4	0
53	Characterization and Outcomes in Patients with Mogamulizumab-Associated Skin Reactions in the MAVORIC Trial. <i>Blood</i> , 2020, 136, 23-24.	1.4	5
54	Role of imaging in low-grade cutaneous B-cell lymphoma presenting in the skin. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 970-976.	1.2	14

#	ARTICLE	IF	CITATIONS
55	Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation. <i>Leukemia and Lymphoma</i> , 2019, 60, 1626-1631.	1.3	23
56	Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma. <i>Blood</i> , 2019, 133, 2121-2129.	1.4	46
57	Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma. <i>Blood Advances</i> , 2019, 3, 187-197.	5.2	40
58	Immunotherapy in mycosis fungoides: opening night or dress rehearsal?. <i>Leukemia and Lymphoma</i> , 2019, 60, 864-866.	1.3	0
59	Breast implant-associated anaplastic large cell lymphoma: Clinical and imaging findings at a large US cancer center. <i>Breast Journal</i> , 2019, 25, 69-74.	1.0	21
60	A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 2834-2834.	1.4	1
61	Expectant Management of Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue (BALT). <i>Blood</i> , 2019, 134, 2826-2826.	1.4	2
62	Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma. <i>Blood</i> , 2019, 134, 4019-4019.	1.4	20
63	Belinostat Induces High Overall Response Rate (ORR) in Patients with Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL). <i>Blood</i> , 2019, 134, 4050-4050.	1.4	4
64	High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed and Refractory Classical Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 2837-2837.	1.4	6
65	Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 1555-1555.	1.4	4
66	Genomic Profiling of Mantle Cell Lymphoma Suggests Poor-Risk Profile Is Present at Diagnosis and Does Not Arise By Tumor Evolution. <i>Blood</i> , 2019, 134, 22-22.	1.4	7
67	Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of CNS Relapse Treated in the Rituximab Era. <i>Blood</i> , 2019, 134, 1619-1619.	1.4	9
68	Characteristics, Treatment Patterns, and Outcomes in Primary Cutaneous Gamma Delta T Cell Lymphoma (PCGDTCL): A Real World Multi-Institutional Analysis of a Rare Malignancy. <i>Blood</i> , 2019, 134, 4028-4028.	1.4	5
69	Contemporary Outcomes in HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: Single-Institution Experience. <i>Blood</i> , 2019, 134, 2850-2850.	1.4	1
70	Incidence of Delayed Seromas and Related Risk of Bia-ALCL in a Cohort of 3521 Breast Cancer Women with Textured Implants Prospectively Followed Long Term. <i>Blood</i> , 2019, 134, 2842-2842.	1.4	0
71	Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 2904-2904.	1.4	2
72	Syngeneic hematopoietic stem cell transplantation from HTLV-1 seropositive twin for adult T-cell leukemia-lymphoma. <i>Bone Marrow Transplantation</i> , 2018, 53, 654-656.	2.4	3

#	ARTICLE	IF	CITATIONS
73	Association of Breast Implants With Anaplastic Large-Cell Lymphoma. <i>JAMA Oncology</i> , 2018, 4, 341.	7.1	8
74	Efficacy of a survivorship-focused consultation versus a time-controlled rehabilitation consultation in patients with lymphoma: A cluster randomized controlled trial. <i>Cancer</i> , 2018, 124, 4567-4576.	4.1	13
75	How I treat breast implant-associated anaplastic large cell lymphoma. <i>Blood</i> , 2018, 132, 1889-1898.	1.4	57
76	Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. <i>Nature Communications</i> , 2018, 9, 2024.	12.8	80
77	T-cell receptor expression and CD45RO+ T-cell infiltrates in primary cutaneous CD4+ T-cell lymphoma and other cutaneous T-cell lymphoproliferative disorders. <i>Histopathology</i> , 2018, 73, 653-662.	2.9	24
78	Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay. <i>Blood Cancer Journal</i> , 2018, 8, 60.	6.2	25
79	Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile. <i>Cancer Immunology Research</i> , 2018, 6, 900-909.	3.4	73
80	Phase I/II Study of CHOEP Plus Lenalidomide As Initial Therapy for Patients with Stage II-IV Peripheral T-Cell Lymphoma: Phase II Results. <i>Blood</i> , 2018, 132, 2899-2899.	1.4	10
81	The Combination of Duvelisib, a PI3K- δ , γ Inhibitor, and Romidepsin Is Highly Active in Relapsed/Refractory Peripheral T-Cell Lymphoma with Low Rates of Transaminitis: Results of Parallel Multicenter, Phase 1 Combination Studies with Expansion Cohorts. <i>Blood</i> , 2018, 132, 683-683.	1.4	28
82	Preliminary Results of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Two Phase IIa Dose Expansion Cohorts in Relapsed/Refractory TP53 Wild-Type Peripheral T-Cell Lymphoma. <i>Blood</i> , 2018, 132, 1623-1623.	1.4	6
83	Superior Clinical Benefit of Brentuximab Vedotin in Mycosis Fungoides Versus Physician's Choice Irrespective of CD30 Level or Large Cell Transformation Status in the Phase 3 ALCANZA Study. <i>Blood</i> , 2018, 132, 1646-1646.	1.4	0
84	Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 193-200.	0.4	27
85	Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. <i>Lancet, The</i> , 2017, 390, 555-566.	13.7	444
86	NCCN Consensus Guidelines for the Diagnosis and Management of Breast Implant-Associated Anaplastic Large Cell Lymphoma. <i>Aesthetic Surgery Journal</i> , 2017, 37, 285-289.	1.6	171
87	Uncommon Variants of T-Cell Lymphomas. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 285-295.	2.2	2
88	The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2017, 23, 4119-4126.	7.0	17
89	Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma. <i>Blood</i> , 2017, 130, 2196-2203.	1.4	111
90	In Vitro, In Vivo, and Parallel Phase I Evidence Support the Safety and Activity of Duvelisib, a PI3K- δ , γ Inhibitor, in Combination with Romidepsin or Bortezomib in Relapsed/Refractory T-Cell Lymphoma. <i>Blood</i> , 2017, 130, 819-819.	1.4	12

#	ARTICLE	IF	CITATIONS
91	A Phase Ib/IIa Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory B- and T-Cell Lymphomas. <i>Blood</i> , 2017, 130, 821-821.	1.4	15
92	Outcomes by CD30 expression in patients with CTCL receiving brentuximab vedotin (BV) vs physician's choice (PC) in the Phase 3 ALCANZA study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7517-7517.	1.6	4
93	Active Surveillance for Newly Diagnosed Nodular Lymphocyte-Predominant Hodgkin Lymphoma. <i>Blood</i> , 2017, 130, 654-654.	1.4	3
94	NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1067-1079.	4.9	107
95	Protocol for a cluster randomised trial of a communication skills intervention for physicians to facilitate survivorship transition in patients with lymphoma. <i>BMJ Open</i> , 2016, 6, e011581.	1.9	61
96	Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population. <i>Leukemia and Lymphoma</i> , 2016, 57, 2575-2583.	1.3	39
97	Central nervous system involvement in T-cell lymphoma: A single center experience. <i>Acta Oncologica</i> , 2016, 55, 561-566.	1.8	44
98	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. <i>Cancer Cell</i> , 2016, 29, 574-586.	16.8	227
99	Managing Patients with Cutaneous B-Cell and T-Cell Lymphomas Other Than Mycosis Fungoides. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 224-233.	2.3	5
100	Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. <i>Blood</i> , 2016, 128, 1458-1464.	1.4	61
101	Prospective Study of ^{18}F -Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma. <i>Journal of Nuclear Medicine</i> , 2016, 57, 728-734.	5.0	41
102	Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 160-168.	1.6	349
103	Intervention Versus Observation: What Is the Appropriate Endpoint? Assessment of Endpoints in Patients with Advanced Stage Follicular Lymphoma Who Are Initially Observed. <i>Blood</i> , 2016, 128, 1777-1777.	1.4	2
104	Pembrolizumab for Treatment of Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Clinical Efficacy in a CItn Multicenter Phase 2 Study. <i>Blood</i> , 2016, 128, 181-181.	1.4	56
105	Brentuximab Vedotin Demonstrates Significantly Superior Clinical Outcomes in Patients with CD30-Expressing Cutaneous T Cell Lymphoma Versus Physician's Choice (Methotrexate or Bexarotene): The Phase 3 Alcanza Study. <i>Blood</i> , 2016, 128, 182-182.	1.4	12
106	Interim PET Evaluation By Deauville Criteria Is an Effective Risk Stratification Tool in PTCL. <i>Blood</i> , 2016, 128, 186-186.	1.4	3
107	Benchmark of Progression Free Survival for Multiple Lines of Therapy in Follicular Lymphoma Treated in the Rituximab Era. <i>Blood</i> , 2016, 128, 2955-2955.	1.4	4
108	A Phase Ib/IIa Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory T-Cell Lymphomas. <i>Blood</i> , 2016, 128, 2991-2991.	1.4	21

#	ARTICLE	IF	CITATIONS
109	Differential Outcome of Patients with Primary Refractory Vs. Relapsed Peripheral T-Cell Lymphoma: Analysis from a Prospective Multicenter US Cohort Study. <i>Blood</i> , 2016, 128, 4150-4150.	1.4	3
110	Outcomes of Follicular Lymphoma Patients By Dynamic FLIPI at Diagnosis and Initial Treatment in the Post-Rituximab Era. <i>Blood</i> , 2016, 128, 4119-4119.	1.4	0
111	Zebras and hen's teeth: recognition and management of rare T and NK lymphomas. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 545-549.	2.5	3
112	mTOR inhibition in T-cell lymphoma: a path(way) forward. <i>Blood</i> , 2015, 126, 284-286.	1.4	7
113	Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 2492-2499.	1.6	394
114	Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. <i>Journal of Clinical Oncology</i> , 2015, 33, 2399-2404.	1.6	97
115	Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and S \ddot{a} zary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. <i>Journal of Clinical Oncology</i> , 2015, 33, 3750-3758.	1.6	235
116	Cutaneous manifestations of human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma: A single-center, retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 293-301.e2.	1.2	35
117	Frontline Treatment of CD30+ Peripheral T-Cell Lymphomas with Brentuximab Vedotin in Combination with CHP: 3-Year Durability and Survival Follow-up. <i>Blood</i> , 2015, 126, 1537-1537.	1.4	5
118	Successful Treatment of Peripheral T-Cell Lymphoma with Allogeneic Stem Cell Transplantation: A Large Single-Center Experience. <i>Blood</i> , 2015, 126, 4392-4392.	1.4	4
119	Refractory T-Cell Prolymphocytic Leukemia with JAK3 Mutation: In Vitro and Clinical Synergy of Tofacitinib and Ruxolitinib. <i>Blood</i> , 2015, 126, 5486-5486.	1.4	10
120	A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Activity in T-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8521-8521.	1.6	23
121	High-Depth, Targeted, Next Generation Sequencing Identifies Novel Genetic Alterations in Cutaneous T-Cell Lymphoma. <i>Blood</i> , 2015, 126, 1485-1485.	1.4	1
122	Results from a Phase 1/2, Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma. <i>Blood</i> , 2015, 126, 2677-2677.	1.4	0
123	Defining the Incidence and Clinical Impact of Genomic Alterations Across Different Histologic Types of Lymphoma Using a Clinically Validated Comprehensive Targeted Sequencing Assay. <i>Blood</i> , 2015, 126, 2668-2668.	1.4	0
124	Veliparib (ABT-888), Bendamustine, and Rituximab (VBR) Is Well Tolerated and Efficacious in Patients with Lymphoma: Final Analysis of a Phase 1b Clinical Trial of VB and a Cohort Expansion of Vbr in Patients with B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 2691-2691.	1.4	0
125	Cutaneous Hemophagocytosis After Alemtuzumab Injection in a Patient With S \ddot{a} zary Syndrome. <i>JAMA Dermatology</i> , 2014, 150, 1021.	4.1	11
126	Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30 ⁺ Peripheral T-Cell Lymphomas: Results of a Phase I Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 3137-3143.	1.6	153

#	ARTICLE	IF	CITATIONS
127	How I treat the peripheral T-cell lymphomas. Blood, 2014, 123, 2636-2644.	1.4	132
128	Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood, 2014, 123, 3095-3100.	1.4	280
129	T Cells in CTCL Have an Exhausted Phenotype While Cutaneous Dendritic Cells Display a Normally Activated Mature Phenotype. Blood, 2014, 124, 1695-1695.	1.4	5
130	Duvelisib (IPI-145), a Phosphoinositide-3-Kinase- $\hat{1}$, $\hat{1}$ ³ Inhibitor, Shows Activity in Patients with Relapsed/Refractory T-Cell Lymphoma. Blood, 2014, 124, 803-803.	1.4	33
131	A Retrospective Analysis of Peripheral T-Cell Lymphoma Treated With the Intention to Transplant in the First Remission. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 664-670.	0.4	39
132	¹⁸ F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma. Leukemia and Lymphoma, 2013, 54, 2163-2167.	1.3	60
133	Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy. Journal of Clinical Oncology, 2012, 30, 631-636.	1.6	571
134	Normalization of pre-ASCT, FDG-PET imaging with second-line, non- \hat{c} cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood, 2012, 119, 1665-1670.	1.4	258
135	Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood, 2012, 119, 4115-4122.	1.4	122
136	Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study. Journal of Clinical Oncology, 2011, 29, 1182-1189.	1.6	535
137	Characterization of T-Cell Lymphomas by FDG PET/CT. American Journal of Roentgenology, 2010, 195, 333-340.	2.2	95
138	A Critical Analysis of Prognostic Factors in Patients with HTLV-1 Adult T-Cell Leukemia/Lymphoma: A Multicenter Clinicopathologic Experience and New Prognostic Score.. Blood, 2008, 112, 1784-1784.	1.4	7
139	A Multicenter Clinicopathologic Experience of HTLV-1 ATLL: A Retrospective 15 Year Review Reveals Little Progress.. Blood, 2007, 110, 3569-3569.	1.4	0
140	Relapsed and Refractory Primary Mediastinal Diffuse Large B-Cell Lymphoma: Outcome with ICE-Based Treatment.. Blood, 2006, 108, 3057-3057.	1.4	5
141	Primary Mediastinal Large B Cell Lymphoma: Elucidating Optimal Therapy and Prognostic Factors; an Analysis in 141 Consecutive Patients Treated at Memorial Sloan Kettering from 1980-1999.. Blood, 2004, 104, 614-614.	1.4	4
142	Peripheral T-cell lymphomas. , 0, , 410-431.		0